These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1004 related articles for article (PubMed ID: 34012108)

  • 1. A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection.
    Miller A; Leach A; Thomas J; McAndrew C; Bentley E; Mattiuzzo G; John L; Mirazimi A; Harris G; Gamage N; Carr S; Ali H; Van Montfort R; Rabbitts T
    Sci Rep; 2021 May; 11(1):10617. PubMed ID: 34012108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency.
    Leach A; Ilca FT; Akbar Z; Ferrari M; Bentley EM; Mattiuzzo G; Onuoha S; Miller A; Ali H; Rabbitts TH
    Antiviral Res; 2021 Oct; 194():105147. PubMed ID: 34375715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.
    Glasgow A; Glasgow J; Limonta D; Solomon P; Lui I; Zhang Y; Nix MA; Rettko NJ; Zha S; Yamin R; Kao K; Rosenberg OS; Ravetch JV; Wiita AP; Leung KK; Lim SA; Zhou XX; Hobman TC; Kortemme T; Wells JA
    Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28046-28055. PubMed ID: 33093202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.
    Ferrari M; Mekkaoui L; Ilca FT; Akbar Z; Bughda R; Lamb K; Ward K; Parekh F; Karattil R; Allen C; Wu P; Baldan V; Mattiuzzo G; Bentley EM; Takeuchi Y; Sillibourne J; Datta P; Kinna A; Pule M; Onuoha SC
    J Virol; 2021 Sep; 95(19):e0068521. PubMed ID: 34287040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.
    Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ
    J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An angiotensin-converting enzyme-2-derived heptapeptide GK-7 for SARS-CoV-2 spike blockade.
    Han S; Zhao G; Wei Z; Chen Y; Zhao J; He Y; He YJ; Gao J; Chen S; Du C; Wang T; Sun W; Huang Y; Wang C; Wang J
    Peptides; 2021 Nov; 145():170638. PubMed ID: 34419496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2.
    Tada T; Fan C; Chen JS; Kaur R; Stapleford KA; Gristick H; Dcosta BM; Wilen CB; Nimigean CM; Landau NR
    Cell Rep; 2020 Dec; 33(12):108528. PubMed ID: 33326798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor.
    Capraz T; Kienzl NF; Laurent E; Perthold JW; Föderl-Höbenreich E; Grünwald-Gruber C; Maresch D; Monteil V; Niederhöfer J; Wirnsberger G; Mirazimi A; Zatloukal K; Mach L; Penninger JM; Oostenbrink C; Stadlmann J
    Elife; 2021 Dec; 10():. PubMed ID: 34927585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2.
    Ahmad S; Waheed Y; Abro A; Abbasi SW; Ismail S
    J Mol Model; 2021 Jun; 27(7):206. PubMed ID: 34169390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico investigation of critical binding pattern in SARS-CoV-2 spike protein with angiotensin-converting enzyme 2.
    Jafary F; Jafari S; Ganjalikhany MR
    Sci Rep; 2021 Mar; 11(1):6927. PubMed ID: 33767306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
    Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants.
    Tanaka S; Nelson G; Olson CA; Buzko O; Higashide W; Shin A; Gonzalez M; Taft J; Patel R; Buta S; Richardson A; Bogunovic D; Spilman P; Niazi K; Rabizadeh S; Soon-Shiong P
    Sci Rep; 2021 Jun; 11(1):12740. PubMed ID: 34140558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiol-based chemical probes exhibit antiviral activity against SARS-CoV-2 via allosteric disulfide disruption in the spike glycoprotein.
    Shi Y; Zeida A; Edwards CE; Mallory ML; Sastre S; Machado MR; Pickles RJ; Fu L; Liu K; Yang J; Baric RS; Boucher RC; Radi R; Carroll KS
    Proc Natl Acad Sci U S A; 2022 Feb; 119(6):. PubMed ID: 35074895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Novel Spike Inhibitors against SARS-CoV-2 Infection.
    Tai LT; Yeh CY; Chang YJ; Liu JF; Hsu KC; Cheng JC; Lu CH
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses.
    Sims JJ; Lian S; Meggersee RL; Kasimsetty A; Wilson JM
    PLoS One; 2022; 17(8):e0271359. PubMed ID: 36006993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
    Xiang Y; Wang M; Chen H; Chen L
    Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
    Nayak SK
    Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.
    Zahradník J; Marciano S; Shemesh M; Zoler E; Harari D; Chiaravalli J; Meyer B; Rudich Y; Li C; Marton I; Dym O; Elad N; Lewis MG; Andersen H; Gagne M; Seder RA; Douek DC; Schreiber G
    Nat Microbiol; 2021 Sep; 6(9):1188-1198. PubMed ID: 34400835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tinocordiside from
    Balkrishna A; Pokhrel S; Varshney A
    Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.